SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Swami Vivekananda

PatientVivekananda
Date of birth1991-01-12
IdentifiersMRN HR-NI032-SYN; SSN (made up) 000-32-9014
Document date2026-03-23
AuthorAnjali Thornbury-Mensah, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Five-week diabetes review before a long journey. [S]

History of Present Illness

Swami Vivekananda returns five weeks after starting metformin and two weeks after starting losartan. His thirst has gone, he wakes to pass urine once a night or not at all, and his fasting readings are 128 to 150 mg/dL. He has had no dizziness on losartan; home blood pressure averages 128/80. He has seen the dietitian twice: he now takes a smaller portion of rice with more dal and vegetables, keeps the sweets offered after worship to a small piece, and has kept two fortnightly fasts with fruit, milk and water, with midday readings of 110 to 140 mg/dL. The screening tests from the preventive visit were negative for HIV, hepatitis C, hepatitis B surface antigen and tuberculosis infection, and he is not immune to hepatitis B. He has decided to take the statin. In a week he leaves for several months of travel and teaching in the mountains, and wants a plan he can follow far from the clinic. [S]

ElementDetail
GlucoseFasting 128 to 150 mg/dL; midday on fast days 110 to 140 mg/dL
Blood pressureHome average 128/80 on losartan
Screening resultsHIV, hepatitis C antibody, hepatitis B surface antigen and interferon-gamma release assay negative; hepatitis B surface antibody negative
UpcomingSeveral months of travel in the mountains from next week

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy much better; weight 73.8 kg
GenitourinaryNegativeNocturia once at most
GastrointestinalNegativeNo loose stools
PsychiatricNegativeEager for the journey; sleep still slow to come

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin extended-release 500 mg tablets: two tablets (1000 mg) with the evening meal, starting with one for the first week1000 mg with the evening mealOral route2026-02-16 to 2026-03-23completedS
Metformin extended-release 500 mg tablets: four tablets (2000 mg) with the evening meal; on fast days with the meal that ends the fast; hold if vomiting, diarrhea or unable to drink2000 mg with the evening mealOral route2026-03-23activeS
Losartan 25 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-09activeS
Atorvastatin 10 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-23activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-03-23Body height172cmS
2026-03-23Body weight73.8kgS
2026-03-23Body mass index (BMI) [Ratio]24.9kg/m2S
2026-03-23Systolic blood pressure128mm[Hg]S
2026-03-23Diastolic blood pressure80mm[Hg]S
2026-03-23Heart rate74/minS
2026-03-23Respiratory rate14/minS
2026-03-23Body temperature36.6CelS
2026-03-23Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-03-23Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
2026-03-23Creatinine [Mass/volume] in Serum or Plasma1mg/dL0.74-1.35 mg/dLNormalS
2026-03-23Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M101mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-03-23Albumin/Creatinine [Mass Ratio] in Urine41mg/g30 to 299 moderately increased; 300 or more severely increasedHighS

Physical Exam

Vital signs recorded on 2026-03-23; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 73.8 kg; blood pressure 128/80, pulse 74
EyesRetinal photographs today: no retinopathy in either eye
CardiovascularRegular; no edema

Problems

ProblemClinical statusVerificationCodeProvenance
Thirst, frequent urination day and night, tiredness and about 4 kg weight loss over two months, with a random glucose of 246 mg/dL; told by physicians a year ago that he had diabetes, never confirmed with modern tests or treated except by diet. Diabetes to be confirmed and classified (type 2, type 1 or slowly progressive autoimmune diabetes) with A1c, fasting glucose, GAD antibodies and C-peptideresolvedconfirmed R73.9S — Synthetic presenting problem anchored to his documented diabetes of the year before. Superseded by the diagnosis at the second visit.
Type 2 diabetes: A1c 9.4 percent and fasting glucose 172 mg/dL, with symptoms; GAD65 antibodies negative and fasting C-peptide preserved (2.6 ng/mL); no ketones. BMI 24.6, in the range where ADA screens Asian Americans. Classified as type 2, not type 1 or slowly progressive autoimmune diabetesactiveconfirmed E11.65S — Synthetic modern confirmation and classification linked to his documented diabetes.
Moderately increased albuminuria on a first sample (urine albumin-to-creatinine ratio 46 mg/g), eGFR normal; to be confirmed on two of three samples over three to six monthsactiveconfirmed R80.9S — Synthetic finding linked to his documented albuminuria; superseded when diabetic kidney disease was confirmed.
Raised blood pressure in clinic (138/86, average of two readings) without a diagnosis of hypertension; home readings to be takenresolvedconfirmed R03.0S — Synthetic finding; not a claim about his real blood pressure.
Hypertension, stage 1: clinic 138/86, 136/86 and 134/84; home average 136/86 over seven days; with moderately increased albuminuria and diabetesactiveconfirmed I10S — Synthetic finding of the modern episode; not a claim about his real blood pressure, which was never recorded.
Long-standing difficulty falling asleep: by his own account he has never been able to fall asleep on getting into bed and lies awake for two hours or more most nights; worse lately with waking to pass urine; rises before dawn for meditationactiveconfirmed G47.00S — Synthetic modern problem linked to his documented lifelong difficulty falling asleep.
Mixed hyperlipidemia: LDL cholesterol 132 mg/dL, triglycerides 228, HDL 36activeconfirmed E78.2S — Synthetic cardiovascular risk factor.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryA1cQuarterly until at goal and after a change in therapyDueDue in three months, during his travels; arrangements made
LaboratoryPotassium and creatinine after starting an ARBOne to two weeks after starting or changing the doseCompleted todayPotassium 4.6; creatinine 1.00; eGFR 101
LaboratoryUrine albumin-to-creatinine ratioTwo of three abnormal over three to six months to confirmCompleted today41 mg/g, the second abnormal sample
LaboratoryLipid panel after starting a statinFour to twelve weeks after startingDueStatin started today; due in six to twelve weeks
ImagingRetinal photographsAt diagnosis, then every one to two yearsCompleted todayNo retinopathy in either eye
ExaminationBlood pressure, weight and BMIEvery visitCompleted today128/80; home 128/80; weight 73.8 kg
Self-managementMedical nutrition therapyAt diagnosis and as neededCompleted todayTwo dietitian visits; a mostly vegetarian plan of his choosing
Self-managementFasting planBefore any religious fastCompleted todayFasts with fruit, milk and water went safely; travel rules agreed
Self-managementSick-day rulesAt diagnosis and before travelCompleted todayHold metformin and losartan when vomiting, diarrhea or unable to drink
Self-managementTobacco useEvery visitCompleted todayNone
Self-managementInsomnia treatmentAt diagnosis of chronic insomniaReferredCognitive behavioral therapy for insomnia by video

Goal progress:

Guideline basis: CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension, hyperlipidemia, CKD and asthma monographs (2026); 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026); 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026); 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026 (2026); Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians (2016); Hassanein M, et al. Diabetes and Ramadan: Practical guidelines 2021. Diabetes Res Clin Pract 2022;185:109185 (PMID 35016991) (2021)

Follow-up: Messages with home readings monthly while he travels. A1c, urine albumin and lipid panel in about three months wherever he is. Diabetes review on his return. Next scheduled visit 2026-10-27: review after seven months away and a week after an asthma attack: A1c, kidneys, lipids, spirometry with bronchodilator response and FeNO; asthma and diabetic kidney disease confirmed; empagliflozin and maintenance-and-reliever inhaler; fasting plan for the coming festival. [S]